GHK-Cu Gene Expression: The Epigenetic Effects of Copper Peptides
Published research reports that GHK-Cu modulates the expression of more than 4,000 genes, including gene sets associated with tissue repair and skin repair pathways. This article collects what the gene-expression literature and the associated trial data report.
What Is GHK-Cu?
GHK-Cu (glycyl-L-histidyl-L-lysine copper) is a naturally occurring copper tripeptide that has been measured in human plasma, saliva, and urine. Published data report that its endogenous concentration declines with age, by roughly 60% between age 20 and 60. In laboratory and preclinical work, GHK-Cu has been reported to influence collagen and elastin synthesis, copper transport, and inflammatory signaling.
It is one of the most widely studied peptides in the copper peptide class, with research spanning collagen biology, wound healing models, hair-growth assays, and tissue remodeling. Throughout this page, "copper peptide" refers to laboratory and published findings, not to a product offered for human use.
Gene Expression and the Reported Study Designs
The landmark gene-expression study reported in the literature used human gene arrays and found that GHK-Cu altered the expression of over 4,000 genes — gene sets involved in collagen synthesis, antioxidant defense, and extracellular-matrix remodeling. Subsequent laboratory work reported downstream effects on fibroblast activity, extracellular-matrix turnover, and stem-cell recruitment in cell and animal models.
Routes described in the published research include topical preparations and systemic administration in animal and in-vitro studies. Reported topical concentrations in cosmetic research typically fall in the 3-5% range. Reported parenteral amounts in animal studies have generally been in the 1-2 mg per day range. These figures are cited as reported study parameters from published research, not as a schedule for anyone to follow.
Evidence Base
GHK-Cu has an extensive published literature, anchored by the gene-expression study reporting modulation of over 4,000 human genes. A Phase 2 wound healing trial adds clinical-stage data to the preclinical body of work, and the copper peptide collagen research underpins much of the current skin repair and wound healing literature.
GHK-Cu is investigational in the systemic applications discussed here. It is not approved for human use by any regulator, no approved dosing exists, and the amounts above are reported from published research as data points — not as a protocol for anyone to follow.
📊 Dosage Calculator & Protocol Chart
Convert reported research quantities into solution volumes for lab reference:
👉 GHK-Cu Calculator — Concentration and volume conversions for reported research quantities.
👉 Full GHK-Cu Research Overview — The published gene-expression data, the Phase 2 trial findings, and the reported study parameters in one place.
Important Disclaimer
This article is for educational and research purposes only. GHK-Cu is investigational in the applications discussed here and has not been approved by the FDA or any other regulator for human use; no approved dosing exists. The information provided here is synthesized from published research, clinical trial data, and community discussions. Nothing on this page is medical advice, and no substance discussed here is offered for human use.
Keywords: GHK-Cu, copper peptide, collagen, wound healing, skin repair
Sources: Published research papers, clinical trial databases, community discussions, peptiq.io educational content